share_log

EFFECT: Others

EFFECT: Others

EFFECT:其他
美股SEC公告 ·  2024/10/07 18:03

Moomoo AI 已提取核心信息

NeuroSense Therapeutics Ltd., a company listed in the United States, has received a Notice of Effectiveness from the Securities and Exchange Commission (SEC) on October 4, 2024. The notice, bearing the accession number 0001213900-24-083478, indicates that the company's submission type POS AM has been officially accepted. The CIK number associated with NeuroSense Therapeutics is 0001875091, and the SEC file number for this notice is 333-273375.
NeuroSense Therapeutics Ltd., a company listed in the United States, has received a Notice of Effectiveness from the Securities and Exchange Commission (SEC) on October 4, 2024. The notice, bearing the accession number 0001213900-24-083478, indicates that the company's submission type POS AM has been officially accepted. The CIK number associated with NeuroSense Therapeutics is 0001875091, and the SEC file number for this notice is 333-273375.
NeuroSense Therapeutics Ltd.,一家在美国上市的公司,于2024年10月4日收到了美国证券交易委员会(SEC)的有效通知。该通知,携带着0001213900-24-083478作为通行证号,表明了公司的提交类型pos Am已经正式被接受。与NeuroSense Therapeutics相关的CIK号码为0001875091,此通知的SEC文件号为333-273375。
NeuroSense Therapeutics Ltd.,一家在美国上市的公司,于2024年10月4日收到了美国证券交易委员会(SEC)的有效通知。该通知,携带着0001213900-24-083478作为通行证号,表明了公司的提交类型pos Am已经正式被接受。与NeuroSense Therapeutics相关的CIK号码为0001875091,此通知的SEC文件号为333-273375。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息